Analystreport

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) had its "buy" rating re-affirmed by analysts at Cowen and Company. They now have a $50.00 price target on the stock.

Supernus Pharmaceuticals, Inc.  (SUPN) 
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.supernus.com